Xenitra Limited (ASX:XEN) has announced it has secured A$1.5 million before costs through a placement of 500,000,000 new fully paid ordinary shares at A$0.003 per share to sophisticated and professional investors. Xenitra specialises in fast-moving consumer goods (FMCG), nutraceuticals, over-the-counter (OTC) medicines, and personal care products, leveraging a channel-optimised sales ecosystem including blockchain-enabled tokenised distribution channels in China. The company is noted for its commercial deployment of Real World Asset (RWA) tokenisation within mainstream Chinese FMCG sales. Investors in the placement will also receive one free-attaching option for every two Placement Shares, exercisable at A$0.004 on or before 2 April 2028, subject to shareholder approval. The offer price represents a 6.25% discount to the 15-trading-day Volume Weighted Average Price (VWAP).
The proceeds from the placement are intended to rapidly accelerate higher-margin sales by expanding inventory procurement, supplier capacity, and order fulfilment. Funds will also support e-commerce activation and brand and distributor onboarding across its OTC Medicines, Food for Special Medical Purposes (FSMP), and OPAL segments. The company reported recent commercial momentum, including approximately A$450,000 in initial Fukang orders fulfilled in July 2026 and a three-year Kangsheng agreement with a minimum A$12 million procurement commitment. Furthermore, a recently announced Joy Charm framework agreement targets A$5 million in FSMP procurement over three years.
Xenitra’s OPAL segment has shown early sales traction, generating over A$1.5 million in tokenised product sales and onboarding more than 500 distribution partners in less than a quarter since launch. This tokenised sales model boasts a substantially higher margin profile compared to Xenitra’s historical nutritionals distribution business. The company also highlighted a stronger operating platform, delivering A$800,000 in positive operating cash flow, a 16% gross-margin improvement, and approximately A$1 million in annualised operating savings in the latest reported quarter. Dr Anthony Noble, Chairman of Xenitra, noted that the raising is deliberately focused on execution, providing working capital to convert established agreements and demand into growing, higher-margin sales.
